Retrospective comparison of survival and responses to Fludarabine, Cytarabine, <scp>GCSF</scp> ( <scp>FLAG</scp> ) in combination with gemtuzumab ozogamicin ( <scp>GO</scp> ) or Idarubicin ( <scp>IDA</scp> ) in patients with newly diagnosed core binding factor ( <scp>CBF</scp> ) acute myelogenous leukemia: <scp>MD</scp> Anderson experience in 174 patients-Reference-Cited by-同舟云学术

Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF ( FLAG ) in combination with gemtuzumab ozogamicin ( GO ) or Idarubicin ( IDA ) in patients with newly diagnosed core binding factor ( CBF ) acute myelogenous leukemia: MD Anderson experience in 174 patients

Published:2022-09-27 Issue:11 Volume:97 Page:1427-1434
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Borthakur Gautam¹^ORCID,Ravandi Farhad¹^ORCID,Patel Keyur²,Wang Xuemei³,Kadia Tapan¹^ORCID,DiNardo Courtney¹^ORCID,Garcia‐Manero Guillermo¹^ORCID,Pemmaraju Naveen¹^ORCID,Jabbour Elias J.¹^ORCID,Takahashi Koichi¹,Ohanian Maro¹^ORCID,Daver Naval¹^ORCID,Alvarado Yesid¹,Brandt Mark¹,Pierce Sherry¹,Kantarjian Hagop¹^ORCID

Affiliation:

1. Department of Leukemia University of Texas MD Anderson Cancer Center Houston Texas USA

2. Department of Hematopathology University of Texas MD Anderson Cancer Center Houston Texas USA

3. Department of Biostatistics University of Texas MD Anderson Cancer Center Houston Texas USA

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26700

Reference26 articles.

1. Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy